No Early Relief for JW Therapeutics from Cancer Wonder Drug
The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
